Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(4):328-332; doi:10.1093/jnci/92.4.328
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ross, R. K.
Right arrow Articles by Pike, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, R. K.
Right arrow Articles by Pike, M. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 4, 328-332, February 16, 2000
© 2000 Oxford University Press


REPORTS

Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin

Ronald K. Ross, Annlia Paganini-Hill, Peggy C. Wan, Malcolm C. Pike

Affiliation of authors: University of Southern California/Norris Comprehensive Cancer Center, Los Angeles.

Correspondence to: Ronald K. Ross, M.D., University of Southern California/Norris Comprehensive Cancer Center, 1441 Eastlake Ave., Rm. 8302B, Los Angeles, CA 90089-9181 (e-mail: ross_r{at}ccnt.hsc.usc.edu).

BACKGROUND: Hormone replacement therapy (HRT) given as unopposed estrogen replacement therapy (ERT) gained widespread popularity in the United States in the 1960s and 1970s. Recent prescribing practices have favored combination HRT (CHRT), i.e., adding a progestin to estrogen for the entire monthly cycle (continuous combined replacement therapy [CCRT]) or a part of the cycle (sequential estrogen plus progestin therapy [SEPRT]). Few data exist on the association between CHRT and breast cancer risk. We determined the effects of CHRT on a woman's risk of developing breast cancer in a population-based, case-control study. METHODS: Case subjects included those with incident breast cancers diagnosed over 41/2 years in Los Angeles County, CA, in the late 1980s and 1990s. Control subjects were neighborhood residents who were individually matched to case subjects on age and race. Case subjects and control subjects were interviewed in person to collect information on known breast cancer risk factors as well as on HRT use. Information on 1897 postmenopausal case subjects and on 1637 postmenopausal control subjects aged 55-72 years who had not undergone a simple hysterectomy was analyzed. Breast cancer risks associated with the various types of HRT were estimated as odds ratios (ORs) after adjusting simultaneously for the different forms of HRT and for known risk factors of breast cancer. All P values are two-sided. RESULTS: HRT was associated with a 10% higher breast cancer risk for each 5 years of use (OR5 = 1.10; 95% confidence interval [CI] = 1.02-1.18). Risk was substantially higher for CHRT use (OR5 = 1.24; 95% CI = 1.07-1.45) than for ERT use (OR5 = 1.06; 95% CI = 0.97-1.15). Risk estimates were higher for SEPRT (OR5 = 1.38; 95% CI = 1.13-1.68) than for CCRT (OR5 = 1.09; 95% CI = 0.88-1.35), but this difference was not statistically significant. Conclusions: This study provides strong evidence that the addition of a progestin to HRT enhances markedly the risk of breast cancer relative to estrogen use alone. These findings have important implications for the risk-benefit equation for HRT in women using CHRT.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. A. Newcomb, K. M. Egan, A. Trentham-Dietz, L. Titus-Ernstoff, J. A. Baron, J. M. Hampton, M. J. Stampfer, and W. C. Willett
Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 864 - 871.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Liang, C. Besch-Williford, R. A. Brekken, and S. M. Hyder
Progestin-Dependent Progression of Human Breast Tumor Xenografts: A Novel Model for Evaluating Antitumor Therapeutics
Cancer Res., October 15, 2007; 67(20): 9929 - 9936.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
K. Kerlikowske, D. L. Miglioretti, D. S. M. Buist, R. Walker, and P. A. Carney
Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
J Natl Cancer Inst, September 5, 2007; 99(17): 1335 - 1339.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
N. Biglia, L. Mariani, L. Sgro, P. Mininanni, G. Moggio, and P. Sismondi
Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
Endocr. Relat. Cancer, September 1, 2007; 14(3): 549 - 567.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. A. Brinton and J. V. Lacey Jr.
Hormones and Breast Cancer: What's the Story?
Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1697 - 1699.
[Full Text] [PDF]


Home page
Hum ReprodHome page
R. L. Tannen, M. G. Weiner, D. Xie, and K. Barnhart
Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy
Hum. Reprod., June 1, 2007; 22(6): 1769 - 1777.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
S. Shantakumar, M. B. Terry, A. Paykin, S. L. Teitelbaum, J. A. Britton, P. G. Moorman, S. B. Kritchevsky, A. I. Neugut, and M. D. Gammon
Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk
Am. J. Epidemiol., May 15, 2007; 165(10): 1187 - 1198.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. L. Mai, J. Sullivan-Halley, G. Ursin, D. O. Stram, D. Deapen, D. Villaluna, P. L. Horn-Ross, C. A. Clarke, P. Reynolds, R. K. Ross, et al.
Physical Activity and Colon Cancer Risk among Women in the California Teachers Study
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 517 - 525.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
A. Z. Steiner, M. Xiang, W. J. Mack, D. Shoupe, J. C. Felix, R. A. Lobo, and H. N. Hodis
Unopposed Estradiol Therapy in Postmenopausal Women: Results From Two Randomized Trials
Obstet. Gynecol., March 1, 2007; 109(3): 581 - 587.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
S. M. Zhang, J. E. Manson, K. M. Rexrode, N. R. Cook, J. E. Buring, and I-M. Lee
Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer
Am. J. Epidemiol., March 1, 2007; 165(5): 524 - 529.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
A. S. Kumar, E. Cureton, V. Shim, T. Sakata, D. H. Moore, C. C. Benz, L. J. Esserman, and E. S. Hwang
Type and Duration of Exogenous Hormone Use A3ects Breast Cancer Histology
Ann. Surg. Oncol., February 1, 2007; 14(2): 695 - 703.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
W. E. Barlow, E. White, R. Ballard-Barbash, P. M. Vacek, L. Titus-Ernstoff, P. A. Carney, J. A. Tice, D. S. M. Buist, B. M. Geller, R. Rosenberg, et al.
Prospective breast cancer risk prediction model for women undergoing screening mammography.
J Natl Cancer Inst, September 6, 2006; 98(17): 1204 - 1214.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S M Hyder
Sex-steroid regulation of vascular endothelial growth factor in breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
K. E. Martin, M. A. Helvie, C. Zhou, M. A. Roubidoux, J. E. Bailey, C. Paramagul, C. E. Blane, K. A. Klein, S. S. Sonnad, and H.-P. Chan
Mammographic Density Measured with Quantitative Computer-aided Method: Comparison with Radiologists' Estimates and BI-RADS Categories
Radiology, September 1, 2006; 240(3): 656 - 665.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Benakanakere, C. Besch-Williford, J. Schnell, S. Brandt, M. R. Ellersieck, A. Molinolo, and S. M. Hyder
Natural and Synthetic Progestins Accelerate 7,12-Dimethylbenz[a]Anthracene-Initiated Mammary Tumors and Increase Angiogenesis in Sprague-Dawley Rats.
Clin. Cancer Res., July 1, 2006; 12(13): 4062 - 4071.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. H. Boekhout, J. H. Beijnen, and J. H.M. Schellens
Symptoms and treatment in cancer therapy-induced early menopause.
Oncologist, June 1, 2006; 11(6): 641 - 654.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. L. Stefanick, G. L. Anderson, K. L. Margolis, S. L. Hendrix, R. J. Rodabough, E. D. Paskett, D. S. Lane, F. A. Hubbell, A. R. Assaf, G. E. Sarto, et al.
Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy
JAMA, April 12, 2006; 295(14): 1647 - 1657.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
L. Rosenberg, J. R. Palmer, L. A. Wise, and L. L. Adams-Campbell
A prospective study of female hormone use and breast cancer among black women.
Arch Intern Med, April 10, 2006; 166(7): 760 - 765.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. H. Gann, A. S. Geiger, I. B. Helenowski, E. F. Vonesh, and R. T. Chatterton
Estrogen and Progesterone Levels in Nipple Aspirate Fluid of Healthy Premenopausal Women: Relationship to Steroid Precursors and Response Proteins
Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 39 - 44.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Gago-Dominguez, J. E. Castelao, M. C. Pike, A. Sevanian, and R. W. Haile
Role of Lipid Peroxidation in the Epidemiology and Prevention of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2829 - 2839.
[Abstract] [Full Text] [PDF]


Home page
J. Epidemiol. Community HealthHome page
K. McPherson and R. Mant
Dose and duration of hormone use: understanding the effects of combined menopausal hormones on breast cancer better, 1976-2004
J. Epidemiol. Community Health, December 1, 2005; 59(12): 1078 - 1079.
[Full Text] [PDF]


Home page
J EndocrinolHome page
F Labrie, V Luu-The, A Belanger, S-X Lin, J Simard, G Pelletier, and C Labrie
Is dehydroepiandrosterone a hormone?
J. Endocrinol., November 1, 2005; 187(2): 169 - 196.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
C. M. Greiser, E. M. Greiser, and M. Doren
Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials
Hum. Reprod. Update, November 1, 2005; 11(6): 561 - 573.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
J. A. Collins, J. M. Blake, and P. G. Crosignani
Breast cancer risk with postmenopausal hormonal treatment
Hum. Reprod. Update, November 1, 2005; 11(6): 545 - 560.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Saitoh, M. Ohmichi, K. Takahashi, J. Kawagoe, T. Ohta, M. Doshida, T. Takahashi, H. Igarashi, A. Mori-Abe, B. Du, et al.
Medroxyprogesterone Acetate Induces Cell Proliferation through Up-Regulation of Cyclin D1 Expression via Phosphatidylinositol 3-Kinase/Akt/Nuclear Factor-{kappa}B Cascade in Human Breast Cancer Cells
Endocrinology, November 1, 2005; 146(11): 4917 - 4925.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. P. Pinheiro, M. D. Holmes, M. N. Pollak, R. L. Barbieri, and S. E. Hankinson
Racial Differences in Premenopausal Endogenous Hormones
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2147 - 2153.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Liang and S. M. Hyder
Proliferation of Endothelial and Tumor Epithelial Cells by Progestin-Induced Vascular Endothelial Growth Factor from Human Breast Cancer Cells: Paracrine and Autocrine Effects
Endocrinology, August 1, 2005; 146(8): 3632 - 3641.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. D. Aupperlee, K. T. Smith, A. Kariagina, and S. Z. Haslam
Progesterone Receptor Isoforms A and B: Temporal and Spatial Differences in Expression during Murine Mammary Gland Development
Endocrinology, August 1, 2005; 146(8): 3577 - 3588.
[Abstract] [Full Text] [PDF]


Home page
Int J EpidemiolHome page
C. Stahlberg, E. Lynge, Z. J. Andersen, N. Keiding, B. Ottesen, F. Rank, Y. A. Hundrup, E. B Obel, and A. T. Pedersen
Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy--a prospective observational study
Int. J. Epidemiol., August 1, 2005; 34(4): 931 - 935.
[Full Text] [PDF]


Home page
J EndocrinolHome page
S R Davis, I Dinatale, L Rivera-Woll, and S Davison
Postmenopausal hormone therapy: from monkey glands to transdermal patches
J. Endocrinol., May 1, 2005; 185(2): 207 - 222.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. S. Tworoger, S. A. Missmer, R. L. Barbieri, W. C. Willett, G. A. Colditz, and S. E. Hankinson
Plasma Sex Hormone Concentrations and Subsequent Risk of Breast Cancer Among Women Using Postmenopausal Hormones
J Natl Cancer Inst, April 20, 2005; 97(8): 595 - 602.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. Wu, S. Brandt, and S. M. Hyder
Ligand- and Cell-Specific Effects of Signal Transduction Pathway Inhibitors on Progestin-Induced Vascular Endothelial Growth Factor Levels in Human Breast Cancer Cells
Mol. Endocrinol., February 1, 2005; 19(2): 312 - 326.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. A. Colditz
Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer
Clin. Cancer Res., January 15, 2005; 11(2): 909s - 917s.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. K. Dunn, D. L. Wickerham, and L. G. Ford
Prevention of Hormone-Related Cancers: Breast Cancer
J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
C. L. Pearce, J. N. Hirschhorn, A. H. Wu, N. P. Burtt, D. O. Stram, S. Young, L. N. Kolonel, B. E. Henderson, D. Altshuler, and M. C. Pike
Clarifying the PROGINS Allele Association in Ovarian and Breast Cancer Risk: A Haplotype-Based Analysis
J Natl Cancer Inst, January 5, 2005; 97(1): 51 - 59.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Q. Ji, C. Aoyama, Y.-D. Nien, P. I. Liu, P. K. Chen, L. Chang, F. Z. Stanczyk, and A. Stolz
Selective Loss of AKR1C1 and AKR1C2 in Breast Cancer and Their Potential Effect on Progesterone Signaling
Cancer Res., October 15, 2004; 64(20): 7610 - 7617.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
Breast Cancer
Obstet. Gynecol., October 1, 2004; 104(4_suppl): 11S - 16S.
[Full Text] [PDF]


Home page
JAMAHome page
K. L. Brubaker
Effects of Estrogen-Only Treatment in Postmenopausal Women
JAMA, August 11, 2004; 292(6): 686 - 686.
[Full Text] [PDF]


Home page
JCOHome page
G. Ursin, S. L. Palla, B. A. Reboussin, S. Slone, C. Wasilauskas, M. C. Pike, and G. A. Greendale
Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
J. Clin. Oncol., July 15, 2004; 22(14): 2842 - 2848.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. E. Wood, T. C. Register, M. S. Anthony, N. D. Kock, and J. M. Cline
Breast and Uterine Effects of Soy Isoflavones and Conjugated Equine Estrogens in Postmenopausal Female Monkeys
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3462 - 3468.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
ESHRE Capri Workshop Group
Hormones and breast cancer
Hum. Reprod. Update, July 1, 2004; 10(4): 281 - 293.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
W. Somboonporn and S. R. Davis
Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women
Endocr. Rev., June 1, 2004; 25(3): 374 - 388.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
The Women's Health Initiative Steering Committee
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
JAMA, April 14, 2004; 291(14): 1701 - 1712.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. M. Muggia
The Emerging Roles of Screening and Prevention in Women's Cancer
Oncologist, April 1, 2004; 9(2): 228 - 231.
[Full Text] [PDF]


Home page
Cancer Res.Home page
J. Wu, J. Richer, K. B. Horwitz, and S. M. Hyder
Progestin-Dependent Induction of Vascular Endothelial Growth Factor in Human Breast Cancer Cells: Preferential Regulation by Progesterone Receptor B
Cancer Res., March 15, 2004; 64(6): 2238 - 2244.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C. Antoine, F. Liebens, B. Carly, A. Pastijn, and S. Rozenberg
Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial
Hum. Reprod., March 1, 2004; 19(3): 741 - 756.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. S. Feigelson, C. R. Jonas, L. R. Teras, M. J. Thun, and E. E. Calle
Weight Gain, Body Mass Index, Hormone Replacement Therapy, and Postmenopausal Breast Cancer in a Large Prospective Study
Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 220 - 224.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. B. Schabath, X. Wu, R. Vassilopoulou-Sellin, A. A. Vaporciyan, and M. R. Spitz
Hormone Replacement Therapy and Lung Cancer Risk: A Case-Control Analysis
Clin. Cancer Res., January 1, 2004; 10(1): 113 - 123.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
J. A. Harvey and V. E. Bovbjerg
Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk
Radiology, January 1, 2004; 230(1): 29 - 41.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
R. M. Bigsby, A. Caperell-Grant, N. Berry, K. Nephew, and D. Lubahn
Estrogen Induces a Systemic Growth Factor Through an Estrogen Receptor-Alpha-Dependent Mechanism
Biol Reprod, January 1, 2004; 70(1): 178 - 183.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Kerlikowske, D. L. Miglioretti, R. Ballard-Barbash, D. L. Weaver, D. S.M. Buist, W. E. Barlow, G. Cutter, B. M. Geller, B. Yankaskas, S. H. Taplin, et al.
Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population
J. Clin. Oncol., December 1, 2003; 21(23): 4314 - 4321.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
R. VASSILOPOULOU-SELLIN
Breast Cancer and Hormonal Replacement Therapy
Ann. N.Y. Acad. Sci., November 1, 2003; 997(1): 341 - 350.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. R. Daling, K. E. Malone, D. R. Doody, L. F. Voigt, L. Bernstein, P. A. Marchbanks, R. J. Coates, S. A. Norman, L. K. Weiss, G. Ursin, et al.
Association of Regimens of Hormone Replacement Therapy to Prognostic Factors among Women Diagnosed with Breast Cancer Aged 50-64 Years
Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1175 - 1181.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
F. Labrie, M. El-Alfy, L. Berger, C. Labrie, C. Martel, A. Belanger, B. Candas, and G. Pelletier
The Combination of a Novel Selective Estrogen Receptor Modulator with an Estrogen Protects the Mammary Gland and Uterus in a Rodent Model: The Future of Postmenopausal Women's Health?
Endocrinology, November 1, 2003; 144(11): 4700 - 4706.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. M. Gapstur, P. Lopez, L. A. Colangelo, J. Wolfman, L. Van Horn, and R. E. Hendrick
Associations of Breast Cancer Risk Factors with Breast Density in Hispanic Women
Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1074 - 1080.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C.-C. Hong, H. J. Thompson, C. Jiang, G. L. Hammond, D. Tritchler, M. Yaffe, and N. F. Boyd
Val158Met Polymorphism in Catechol-O-methyltransferase Gene Associated with Risk Factors for Breast Cancer
Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 838 - 847.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
H. Olsson, A. Bladstrom, and C. Ingvar
Are Smoking-Associated Cancers Prevented or Postponed in Women Using Hormone Replacement Therapy?
Obstet. Gynecol., September 1, 2003; 102(3): 565 - 570.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. De Vivo, S. E. Hankinson, G. A. Colditz, and D. J. Hunter
A Fu